Over the last two decades, the six-month PFS (progression-free survival) of patients with platinum-resistant ovarian cancer has improved from 30% in chemotherapy-alone [115] to 47% in the chemotherapy plus anti-VEGF [116] to 53% in the chemotherapy plus anti-VEGF plus anti-PD-1 [117]. This evidence concerns the gene PDCD1 and ovarian cancer.